Swiss National Bank Grows Holdings in Replimune Group, Inc. (NASDAQ:REPL)

Swiss National Bank raised its position in Replimune Group, Inc. (NASDAQ:REPL) by 57.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 103,700 shares of the company’s stock after buying an additional 37,800 shares during the period. Swiss National Bank’s holdings in Replimune Group were worth $1,256,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. State Street Corp lifted its stake in shares of Replimune Group by 102.1% in the third quarter. State Street Corp now owns 2,340,042 shares of the company’s stock worth $25,647,000 after acquiring an additional 1,182,181 shares in the last quarter. Baker BROS. Advisors LP increased its holdings in Replimune Group by 10.0% during the 3rd quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock worth $121,057,000 after purchasing an additional 1,000,000 shares during the last quarter. Parkman Healthcare Partners LLC raised its position in shares of Replimune Group by 45.5% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 763,747 shares of the company’s stock valued at $8,371,000 after purchasing an additional 238,747 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Replimune Group by 17.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock valued at $15,657,000 after buying an additional 217,308 shares during the last quarter. Finally, Barclays PLC grew its position in shares of Replimune Group by 165.5% during the third quarter. Barclays PLC now owns 158,491 shares of the company’s stock worth $1,738,000 after buying an additional 98,791 shares in the last quarter. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Stock Down 0.6 %

REPL stock opened at $10.39 on Friday. The firm’s 50-day moving average is $12.67 and its two-hundred day moving average is $12.15. The company has a market capitalization of $800.19 million, a price-to-earnings ratio of -3.38 and a beta of 1.30. Replimune Group, Inc. has a 52 week low of $4.92 and a 52 week high of $17.00. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.09). On average, analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. JPMorgan Chase & Co. upped their price target on shares of Replimune Group from $16.00 to $18.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. HC Wainwright boosted their price target on Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a report on Thursday, February 13th. Jefferies Financial Group increased their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, December 4th. Finally, BMO Capital Markets boosted their price objective on Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a research report on Wednesday, January 22nd. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $19.43.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.